ROCCHETTI MARCELLA

Arici, M., Hsu, S., Ferrandi, M., Barassi, P., Ronchi, C., Torre, E., et al. (2024). Selective SERCA2a activator as a candidate for chronic heart failure therapy. JOURNAL OF TRANSLATIONAL MEDICINE, 22(1) [10.1186/s12967-024-04874-9]. Dettaglio

Zarbo, C., Stolarski, M., Zamparini, M., Damiani, S., Casiraghi, L., Rocchetti, M., et al. (2023). Time perspective affects daily time use and daily functioning in individuals with Schizophrenia Spectrum Disorders: Results from the multicentric DiAPAson study. JOURNAL OF PSYCHIATRIC RESEARCH, 160(April 2023), 93-100 [10.1016/j.jpsychires.2023.02.012]. Dettaglio

Arici, M., Ferrandi, M., Barassi, P., Hsu, S., Torre, E., Luraghi, A., et al. (2023). Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function. THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 384(1), 231-244 [10.1124/jpet.122.001335]. Dettaglio

Altomare, C., Bartolucci, C., Sala, L., Balbi, C., Burrello, J., Pietrogiovanna, N., et al. (2023). A dynamic clamping approach using in silico IK1 current for discrimination of chamber-specific hiPSC-derived cardiomyocytes. COMMUNICATIONS BIOLOGY, 6(1) [10.1038/s42003-023-04674-9]. Dettaglio

Luraghi, A., Ferrandi, M., Barassi, P., Arici, M., Hsu, S., Torre, E., et al. (2022). Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure. JOURNAL OF MEDICINAL CHEMISTRY, 65(10), 7324-7333 [10.1021/acs.jmedchem.2c00347]. Dettaglio